Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats

Journal of Nutrition

Volumn 139, Issue 5, 2009, Pages 958-964

  Guo, Hui Yuan ^a,b   Jiang, Lu ^a,b   Ibrahim, Salam A ^c   Zhang, Lian ^d   Zhang, Hao ^a,b   Zhang, Ming ^a,b   Ren, Fa Zheng ^a,b  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c NORTH CAROLINA A AND T STATE UNIVERSITY   (United States)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BOVINE SERUM ALBUMIN; CALCITONIN; CALCIUM; ESTRADIOL; INTERLEUKIN 6; LACTOFERRIN; TUMOR NECROSIS FACTOR ALPHA; AMINO ACID; DEOXYPYRIDINOLINE; OSTEOCALCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRUCTURE; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; FEMALE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; RAT; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; TRABECULAR BONE; ANIMAL; BIOMECHANICS; BLOOD; BONE; CELL DIVISION; DRUG EFFECT; HISTOLOGY; MICRO-COMPUTED TOMOGRAPHY; OSTEOBLAST; PHYSIOLOGY; URINE;

BOVINAE; RATTUS;

AMINO ACIDS; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCIUM; CELL DIVISION; ESTRADIOL; FEMALE; INTERLEUKIN-6; LACTOFERRIN; OSTEOBLASTS; OSTEOCALCIN; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

EID: 65349196069     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.108.100586     Document Type: Article

References (40)

1. Consensus development conference. Prophylaxis and treatment of osteoporosis. Am J Med. 1991;90:107-10.
2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-7.
3. Grey A, Reid IR. Emerging and potential therapies for osteoporosis. Expert Opin Investig Drugs. 2005;14:265-78.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
5. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334-41.
6. Metz-Boutigue MH, Jolles J, Mazurier J, Schoentgen F, Legrand D, Spik G, Montreuil J, Jolles P. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem. 1984;145:659-76.
7. Nagasawa T, Kiyosawa I, Kuwahara K. Amounts of lactoferrin in human colostrum and milk. J Dairy Sci. 1972;55:1651-9.
8. Nichols BL, McKee KS, Henry JF, Putman M. Human lactoferrin stimulates thymidine incorporation into DNA of rat crypt cells. Pediatr Res. 1987;21:563-7.
9. Crouch SP, Slater KJ, Fletcher J. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood. 1992;80:235-40.
10. Bi BY, Lefebvre AM, Dus D, Spik G, Mazurier J. Effect of lactoferrin on proliferation and differentiation of the Jurkat human lymphoblastic T cell line. Arch Immunol Ther Exp (Warsz). 1997;45:315-20.
11. Farnaud S, Evans RW. Lactoferrin: a multifunctional protein with antimicrobial properties. Mol Immunol. 2003;40:395-405.
12. Kimber I, Cumberbatch M, Dearman RJ, Headon DR, Bhushan M, Griffiths CE. Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochem Cell Biol. 2002;80: 103-7.
13. Frydecka I, Zimecki M, Bocko D, Kosmaczewska A, Teodorowska R, Ciszak L, Kruzel M, Wlodarska-Polinsk J, Kuliczkowski K, et al. Lactoferrin-induced up-regulation of zeta (zeta) chain expression in peripheral blood T lymphocytes from cervical cancer patients. Anti-cancer Res. 2002;22:1897-901.
14. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med. 1999;37:281-6.
15. Brock JH. The physiology of lactoferrin. Biochem Cell Biol. 2002;80:1-6.
16. Grey A, Banovic T, Zhu Q, Waston M, Callon K, Palmano K, Ross J, Naot D, Reid IR, et al. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol. 2004;18:2268-78.
17. Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, Watson M, Lin JM, Tong PC, et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology. 2004;145:4366-74.
18. Cornish J. Lactoferrin promotes bone growth. Biometals. 2004;17:331-5.
19. Naot D, Grey A, Reid IR, Cornish J. Lactoferrin: a novel bone growth factor. Clin Med Res. 2005;3:93-101.
20. Grey A, Zhu Q, Waston M, Callon K, Cornish J. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol Cell Endocrinol. 2006;251:96-102.
21. Lorget F, Clough J, Oliveira M, Daury M, Sabokbar A, Offord E. Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun. 2002;296:261-6.
22. Zimecki M, Spiegel K, Wlaszczyk A, Kubler A, Kruzel ML. Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-a and IL-6 by peripheral blood cells. Arch Immunol Ther Exp (Warsz). 1999;47:113-8.
23. Cai DJ, Zhao YD, Glasier J, Cullen D, Barnes S, Turner CH, Wastney M, Weaver CM. Comparative effect of soy protein, soy lsoflavones, and 17β-Estradiol on bone metabolism in adult ovariectomized rats. J Bone Miner Res. 2005;20:828-39.
24. Koefoed M, Ito H, Gromov K, Reynolds DG, Awad HA, Rubery PT, Ulrich-Vinther M, Soballe K, Guldberg RE, et al. Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther. 2005;12:212-8.
25. Tomita M, Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci. 1991;74:4137-42.
26. Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, Reid IR. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277:E779-83.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
28. Kinney JH, Haupt DL, Balooch M, Ladd AJC, Ryaby JT, Lane NE. Three-dimensional morphometry of the L±vertebra in the ovariecto- mized rat model of osteoporosis: biomechanical implications. J Bone Miner Res. 2000;15:1981-91.
29. Schecroun N, Pidoux E, Horne W, Hernandez-Lagunas L, Baron R, Cressent M. Biological properties of salmon calcitonin IV. J Bone Miner Res. 1999;14:1425-31.
30. Van Cromphaut SJ, Rummens K, Stockmans I, Herck EV, Dijcks F, Ederveen A, Carmeliet P, Verhaeghe J, Bouillon R, et al. Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent mechanisms. J Bone Miner Res. 2003;18:1725-36.
31. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy DD. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factor. Nature. 1986;319:516-8.
32. Lorenzo J. Interactions between immune and bone cells: new insights with many remaining questions. J Clin Invest. 2000;106:749-52.
33. Debbabi H, Dubarry M, Lerautureau M, Tome D. Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res. 1998;65:283-93.
34. Sfeir RM, Dubarry M, Boyaka PN, Rautureau M, Tome D. The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr. 2004;134:403-9.
35. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin ±in vivo. Int J Exp Pathol. 1993;74:433-9.
36. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS induced inflammatory responses in mice. Clin Exp Immunol. 2002;130:25-31.
37. Zimecki M, Wlaszczyk A, Zagulski T, Kubler A. Lactoferrin lowers serum interleukin 6 and tumor necrosis factor alpha levels in mice subjected to surgery. Arch Immunol Ther Exp (Warsz). 1998;46:97-104.
38. Ligo M, Kuhara T, Ushida Y, Sekine K, Moore MA, Tsuda H. Inhibitory effects of bovine lactoferrin on colon carcinoma 2±lung metastasis in mice. Clin Exp Metastasis. 1999;17:35-40.
39. Kuwata H, Yamauchi K, Teraguchi S, Ushida Y, Shimokawa Y, Toida T, Hayasawa H. Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J Nutr. 2001;131:2121-7.
40. Kuwata H, Yip TT, Tomita M, Hutchens W. Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim Biophys Acta. 1998;1429:129-41.